Ocugen Climbs on Phase 3 COVID Vaccine Data, Hitting Back at Delta Variant

Source: FierceBiotech

After seeing its stock fall consistently over the past few months, Ocugen and partner Bharat Biotech have posted some encouraging data from their pandemic vaccine Covaxin, according to a FierceBiotech report. 

The latest look from its late-stage of test of the virion-inactivated COVID-19 vaccine, which already has restricted emergency use in India, saw vaccine efficacy in mild, moderate and severe COVID-19 disease of 77.8%, with efficacy against severe COVID-19 disease alone of 93.4%.

Read the full article. 


Related Content